Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors
Covariates include age, BMI, systolic blood pressure, diastolic blood pressure, marital status, education level, smoking status, physical activity, total cholesterol and TAG
Schedule: Twice-weekly subcutaneous injections for 812 weeks (extend to 16 weeks if desired)
As monotherapy , a multicentre, randomised, double-blind, placebo-controlled and active-controlled Phase 2 dose-finding trial enrolled 706 adults with overweight or obesity (without diabetes) to once-weekly subcutaneous cagrilintide across doses of 0.3 to 4.5 mg over 26 weeks
Please keep the vial refrigerated for optimal efficacy